Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

Authors performed an investigation of the long–term immunogenicity of 13–valent pneumococcal conjugate vaccine (PCV13) in pneumococcal vaccine–naive older adults as part of Community–Acquired Pneumonia Immunization Trial in Adults (CAPiTA). In immunocompetent adults ≥65 years of age, PCV13 elicited significant increases in OPA titers and IgG concentrations that persisted 2 years postvaccination for all 13 serotypes, regardless of age and comorbidity.